Literature DB >> 7995327

Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia.

F Albertioni1, L Herngren, G Juliusson, J Liliemark.   

Abstract

The plasma protein binding of 2-chloro-2'-deoxyadenosine (CdA) at 37 degrees C was studied by ultrafiltration in 5 healthy volunteers, in 11 patients with haematological malignancies and in purified protein preparations. In the patients, the binding of CdA to plasma proteins was 25.0% and in healthy subjects it was 21.1%. In a solution of human serum albumin (40 g.l-1), 24.3% CdA was bound, but less than 5% was bound in a solution of alpha 1-acid-glycoprotein (0.7 g.l-1). No dependence of binding on the concentration of CdA was found within a range 25-1000 nmol.l-1. In conclusion, due to its limited binding to plasma proteins, any change in the binding of CdA is unlikely to have a major influence on its pharmacological effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995327     DOI: 10.1007/BF00196117

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.

Authors:  J Liliemark; F Albertioni; M Hassan; G Juliusson
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

2.  Determination of 2-chloro-2'-deoxyadenosine in human plasma.

Authors:  J Liliemark; B Pettersson; G Juliusson
Journal:  Biomed Chromatogr       Date:  1991-11       Impact factor: 1.902

3.  On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.

Authors:  J Liliemark; G Juliusson
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

4.  Effect of plasma protein and tissue binding on the biologic half-life of drugs.

Authors:  M Gibaldi; G Levy; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

Review 5.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 6.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

7.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.

Authors:  F Albertioni; G Juliusson; J Liliemark
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  8 in total
  3 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

Authors:  V Reichelová; G Juliusson; T Spasokoukotskaja; S Eriksson; J Liliemark
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  Development of oral immunomodulatory agents in the management of multiple sclerosis.

Authors:  Richard Nicholas; Paolo Giannetti; Ali Alsanousi; Tim Friede; Paolo A Muraro
Journal:  Drug Des Devel Ther       Date:  2011-05-10       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.